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Abstract
The goals of Epilepsy Benchmark Area III involve identifying areas that are ripe for progress in terms of controlling seizures and
patient symptoms in light of the most recent advances in both basic and clinical research. These goals were developed with an
emphasis on potential new therapeutic strategies that will reduce seizure burden and improve quality of life for patients with
epilepsy. In particular, we continue to support the proposition that a better understanding of how seizures are initiated, pro-
pagated, and terminated in different forms of epilepsy is central to enabling new approaches to treatment, including pharma-
cological as well as surgical and device-oriented approaches. The stubbornly high rate of treatment-resistant epilepsy—one-third
of patients—emphasizes the urgent need for new therapeutic strategies, including pharmacological, procedural, device linked, and
genetic. The development of new approaches can be advanced by better animal models of seizure initiation that represent salient
features of human epilepsy, as well as humanized models such as induced pluripotent stem cells and organoids. The rapid advances
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in genetic understanding of a subset of epilepsies provide a path to new and direct patient-relevant cellular and animal models,
which could catalyze conceptualization of new treatments that may be broadly applicable across multiple forms of epilepsies
beyond those arising from variation in a single gene. Remarkable advances in machine learning algorithms and miniaturization of
devices and increases in computational power together provide an enhanced opportunity to detect and mitigate seizures in real
time via devices that interrupt electrical activity directly or administer effective pharmaceuticals. Each of these potential areas for
advance will be discussed in turn.
Keywords
NINDS benchmarks for epilepsy research, Epilepsy Benchmarks, progress in epilepsy research, seizure mechanisms, refractory
epilepsy, genetics, real-time management of seizures, epilepsy therapies
Introductory Vignette by Amanda Jaksha:
Clinical Trials—A Parent’s Perspective
CDKL5 deficiency disorder (CDD) is a rare developmental and
epileptic encephalopathy that typically presents with refractory
epilepsy, often epileptic spasms without hypsarrhythmia, in the
first days or months of life. In 2012, at the age of 6.5 years, my
daughter was diagnosed with CDD. By then, she had endured
thousands of seizures and failed most available AEDs. She nar-
rowly escaped liver failure from drug rash with eosinophilia and
systemic symptoms syndrome upon the introduction of a
second-generation AED adjunct therapy. Also seasoned in
failed treatments for comorbidities of dysmotility, behavior, and
sleep, we become cynical about introducing any compounds.
We recently convened serious discussions about seizure
control due to a decrease in her quality of life, with puberty
onset increasing daily seizure activity. My daughter was a can-
didate for 2 clinical trials, one a blinded, placebo-controlled
study and the other an open-label investigation. It was a simple
choice as there was no time for a placebo. Upon completion of
the observation period, she received her first dose around 6
weeks later. There was an immediate increase in seizures, and
a few days later, a gradual reduction from baseline activity
emerged. Anxiety and vocal stimming behaviors decreased
substantially, and her gross motor skills became more fluid and
sustained. With these improvements, she enjoys more func-
tional access to community and more independence with the
ability to ambulate longer distances. She also appreciates
expressing more of her voice as she uses her eyes to talk via
an eye-gaze communication (AAC) device. She can tell me to
go away or that she feels diabolical with higher efficiency and
less frustration. While her epilepsy remains refractory, to our
surprise and delight, her quality of life has increased beyond
anything imagined with this assumed improvement in other
neuronal functions.
—Amanda Jaksha, International Foundation for CDKL5
Research
Introduction to Area III
The goals of Epilepsy Benchmark Area III involve identifying
areas that are ripe for progress in terms of controlling seizures
and patient symptoms in light of the most recent advances in
both basic and clinical research. These goals were developed
with an emphasis on potential new therapeutic strategies that
will reduce seizure burden and improve quality of life for
patients with epilepsy. In particular, we continue to support the
proposition1 that a better understanding of how seizures are
initiated, propagated, and terminated in different forms of epi-
lepsy is central to enabling new approaches to treatment,
including pharmacological as well as surgical and device-
oriented approaches. The stubbornly high rate of treatment-
resistant epilepsy—one-third of patients2—emphasizes the
urgent need for new therapeutic strategies, including pharmaco-
logical, procedural, device linked, and genetic. The develop-
ment of new approaches can be advanced by better animal
models of seizure initiation that represent salient features of
human epilepsy,3 as well as humanized models such as induced
pluripotent stem cells (iPSCs) and organoids.4 The rapid
advances in genetic understanding of a subset of epilepsies5,6
provide a path to new and direct patient-relevant cellular and
animal models, which could catalyze conceptualization of new
treatments that may be broadly applicable across multiple forms
of epilepsies beyond those arising from variation in a single
gene. Remarkable advances in machine learning algorithms and
miniaturization of devices and increases in computational power
together provide an enhanced opportunity to detect andmitigate
seizures in real time7,8 via devices that interrupt electrical activ-
ity directly or administer effective pharmaceuticals. Each of
these potential areas for advance will be discussed in turn.
Seizure Mechanisms
There remains a pressing need to understand the initiation,
propagation, and termination of seizures at the network level
in different forms of epilepsy in order to devise better treatment
strategies. Understanding how neuronal synchrony within a
microcircuit reaches a critical threshold, subsequently allowing
it to entrain larger populations of neurons, could suggest novel
mechanisms that can be engaged to terminate a seizure.
Although there are volumes of work on this topic over the
decades,9-11 new advances in stratification of epilepsies
through pharmacogenomics12 and genetic analysis13 could pro-
vide new understanding of mechanisms in models relevant for
human disease. Advances in computational models have
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reached the point where both interictal and ictal activities can
be reliably generated from the same network. The predictions
of these models can now be practically verified.14,15 Additional
insights may also follow from a determination of the relative
contribution of shared cellular and network mechanisms to
different models. Similarly, advances in modeling the process
of epileptogenesis suggest interesting new mechanisms, yet
highlight the complexity of the problem.16 These mechanisms
could lead to the testing of more effective therapies.
Status epilepticus remains a clinical challenge, with a subset
of patients proving refractory to multiple treatments17 despite
the development and approval of new antiseizure medications
(ASMs). The persistent seizures associated with this condition
focus attention on how little we understand about the processes
of seizure initiation, maintenance, and termination. Thus,
insight into mechanisms that maintain hypersynchronous firing
for prolonged durations in the face of adaptive changes,
exhaustion of energy stores, and mounting inflammatory cas-
cades may allow improved treatments that can stop ongoing
seizures and status epilepticus. Although a variety of processes
are considered relevant to status epilepticus,18-20 we still lack a
clear assessment of the relative contributions of each one. New
mechanism-based targets would improve our ability to effec-
tively terminate status epilepticus.
An impressive amount of electrophysiological analysis of
mechanisms that can lead to hypersynchronous firing has been
performed either in vivo in adult animals or ex vivo in brain
slices from rodents that range in age from adolescence to young
adulthood. There is a growing opportunity to complement ani-
mal tissue work with acute and organotypic human brain slices
obtained following surgical resection21,22 as well as in vivo
recordings from depth electrode–implanted patients.23 How-
ever, there is a stark lack of information in some areas, for
example, related to features of the neonatal brain that contrib-
ute to hypersynchronous activity, apart from changes in chlor-
ide (Cl) gradients that render GABAergic transmission
excitatory.24,25 Early-life seizures are an important therapeutic
target because many epileptic encephalopathies become appar-
ent early in life. In particular, understanding the mechanisms
underlying hypersynchronous firing in neonatal brain could
lead to the development of therapies that are more effective
for neonatal seizures as opposed to simply modifying the dos-
ing of drugs that showed a positive signal in clinical trials in
adults with epilepsy. Strategies could involve use of repurposed
drugs, specific combinations of therapies, or the development
of new therapies, noting, however, the substantial hurdles for
bringing to market drugs for a pediatric population. Although
the first uncontrolled trial of the repurposed drug bumetanide
did not show efficacy,26 this finding was controversial,27,28 and
the results of a subsequent blinded controlled trial of bumeta-
nide is reported to be more promising (clinicaltrials.
govNCT00830531). To this end, new genetic models of ultra-
rare variants in genes capable of producing seizures and hyper-
excitability may provide new models of mechanisms
underlying development of an epileptic focus in neonatal ani-
mals. Indeed, multiple animal models of genetic epilepsies
show seizure activity at an early age, providing an opportunity
to study epilepsy in the developing brain.
The role of inflammation has been increasingly recognized in
a wide range of neurological diseases, including epilepsy and
status epilepticus.29-31 Neuroinflammation can impact network
excitability in several ways, including activating microglia,
reshaping synaptic input, and altering ion channel function.
Thus, there is the potential to explore anti-inflammatory thera-
pies for use in conjunction with conventional ASMs in the
chronic therapy of epilepsies that are thought to be inflammatory
in nature, such as Rasmussen encephalitis.32 In addition, the
utility of some treatments for seizure categories not convention-
ally believed to be related to inflammatory mechanisms should
be explored. This has the potential to perhaps reduce the refrac-
tory rate, or increase seizure control, for some groups of patients.
There is an emerging appreciation of autoimmune encepha-
litis33 that involves antibodies against epitopes in proteins that
control neuronal excitability, such as the NMDA receptor,34
GAD65,35 and GABAB receptor subunits.
36,37 Patients with
antibody-mediated encephalitis often exhibit nonconvulsive
seizures, in addition to memory loss, psychiatric symptoms,
and other features. For some epitopes, preclinical data validate
the immunoglobulin G fraction as causative for seizures. Treat-
ment with immunotherapy can be effective, but additional ther-
apeutic strategies are needed.36,38 The full extent of this clinical
condition is just now becoming appreciated, and it remains
almost certainly underdiagnosed at this point. Thus, future
work should focus on earlier recognition of these presentations
and early and robust diagnosis in order to achieve potentially
effective treatment before the development of irreversible
sequelae of neuroinflammation.
Genetic Advances
An important consequence of the many genetic advances that
are transforming clinical neurology39 is their ability to suggest
new animal models to investigate the underlying disease
mechanisms, including compensatory mechanisms that can
contribute to a seizure focus.40 Such models are relevant to
genetic human epilepsies and serve as an important comple-
ment to the acquired models of focal epilepsy (eg, pharmaco-
logically induced seizure models) that have become the
mainstay for development of in vivo models of chronic recur-
ring seizures. Animal models of single-gene defects offer an
opportunity to evaluate windows for therapeutic intervention in
patients who have these specific variants, with the possibility
that some therapies will be more broadly applicable to multiple
epilepsies. In addition, such models offer a new opportunity to
study common mechanisms that underlie maladaptive plasti-
city and can lead to generation of a seizure focus. Novel gene
expression programs may be triggered by genetic deficiencies
that engage similar mechanisms, and understanding these
might allow better understanding of antiepileptic drug utility.40
In this respect, the intersection of gene expression data sets
may inform key pathways that establish seizure foci regardless
of the initial genetic defect driving seizures. In addition,
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genetic animal models can facilitate the evaluation and valida-
tion of strategies such as antisense oligonucleotides, gene
replacement, and gene augmentation. The success of new
genetic treatments of spinal muscular atrophy with intrave-
nously delivered gene replacement via adeno-associated viral
vector in very young infants41 has created hope for many
patients that these therapies can correct other neurological con-
ditions, stimulating work on this problem in academia and,
importantly, in industry. Thus, there are actionable opportuni-
ties for genetic therapies for epilepsy on the horizon.
In addition to the value of new models suggested by genetic
analysis, there are several opportunities to exploit advances in
diagnostic and therapeutic genetic approaches. There are now
multiple examples of strategies one could use to develop gene
therapy employing viral vectors to treat focal and generalized
epilepsies in animal models in which a missense variant or
truncating mutation has modified the function of a target gene
or reduced the gene dose.42 Other innovative uses of gene
therapy include introduction of potassium channels that could
reduce excitability, as well as engineering cells to release neu-
roactive molecules that can counteract excessive excitabil-
ity.43,44 As more animal models are developed for different
genes, there will be opportunities to test fundamental
approaches that supplement underexpressed alleles or proteins
with reduced function, as well as editing gene approaches to
correct identified defects. These strategies will require demon-
stration of utility in animals with measurable defects, and the
results will speak to the important question in epilepsy around
whether symptoms are driven by the genetic defect, are a fea-
ture of maladaptive compensation, or reflect some combination
of both. That is, there is a need for proof-of-concept data for
oligonucleotide and antisense therapies for application in the
treatment of genetically defined monogenic epilepsies, as well
as data on effectiveness of the timing of treatment in the con-
text of the development of a seizure focus. Advances are
needed in genetic therapy using virus delivery vectors that are
already approved for other payloads and access both brain and
spinal cord following intrathecal administration. The rare
genetic epilepsies might provide a test case for intervention,
which can be evaluated in iPSC-based models in vitro, orga-
noids derived from iPSC cells, and animal models now.
One opportunity that the accessibility of multiple new
genetic models of human variants associated with epilepsy
offers is evaluation of repurposed drugs. This requires a com-
prehensive functional evaluation of the effects of rare variants
in vitro, which for ion channels is accessible. Functional eva-
luation of drug sensitivity of variant proteins will inform poten-
tial use of therapeutics, as will knowledge of the nature of the
net functional effects as either gain of function or loss of func-
tion, or indeterminant.45-49 Genetic models—from cellular
models to zebrafish and mouse models—harboring variants can
then be screened for actions of Food and Drug Administration
(FDA)-approved medications for efficacy in reducing electro-
encephalogram abnormalities and seizures46,50,51 as a step
toward using pharmacological treatments. If the models cap-
ture patient-relevant features of epileptogenesis, early
treatment within a vulnerable window might have long-
lasting consequences.
In addition to these pharmacological approaches, bioinfor-
matics coupled with large-scale data sets have driven the devel-
opment of computational resources52,53 that can suggest
candidate drugs in the FDA library from patterns of changes in
gene expression. Moreover, evaluation of multiple drugs in mul-
tiple models might identify candidate drugs as add-on therapies
that could be used more broadly than for just for rare genetic
conditions. Indeed, a large number of epilepsy models have been
or are being made from various genes identified in patients with
rare epilepsies (eg, sodium channels, potassium channels, post-
synaptic ligand-gated ion channels, synaptic proteins), whichwill
provide patient-relevant models in which to assess new pharma-
cological strategies. These same models can be used to under-
stand developmental compensation, transformation of the foci
with time, and pharmacological sensitivity. It seems likely that
some compensatory mechanisms will be shared across these dif-
ferentmodels andmay inform treatment of refractory epilepsy. In
addition to rodent models, use of companion models and organ-
isms (fly, zebrafish, mice, iPSC-derived neuronal cultures, and
organoids) could provide faster and more efficient drug screen-
ing43 as well as evaluation of compensatory mechanisms.
The advances in genetic analysis could also expand our
understanding of acquired epilepsies and yield insight into
whether persons with genetic predispositions may be at greater
risk and merit more aggressive treatment and management.
This will require concerted effort to capture genetic informa-
tion from patients with acute events that lead to seizures or
increase seizure risk. With a sufficient sample size, some com-
mon polygenic factors might emerge, suggesting genes or
genetic patterns that imply risk.6 In some cases, one might
consider treating the predisposition if it can be identified as
the first step to gain adequate seizure control before consider-
ing, for example, epilepsy surgery. This same form of analyses
could be applied to traumatic brain injury, stroke, hypoxia, and
other insults that enhance the likelihood of future seizures.
Refractory Epilepsy
About one-third of patients with epilepsy are in part or fully
refractory to treatment, creating an enormous medical, social,
and economic burden. Thus, an essential aspect of any future
prioritization is the need to develop new or improve existing
antiseizure therapies for patients with refractory epilepsy.
Efforts should include analysis of sequencing data for patients
who fail to show adequate improvement following surgical
intervention to determine whether there are shared risk factors,
as well as those who successfully respond. Approaches that
deserve consideration in this regard include conventional drug
development, selection of surgical patients, and genetic analy-
sis of both responsive and refractory patients. Toward this end,
several new drugs have entered clinical use following FDA
approval, including cannabidiol for Dravet and Lennox-
Gastaut syndromes,54,55 nasally administered midazolam for
seizure clusters,56 stiripentol for Dravet syndrome,57 and
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everolimus for seizures in patients with tuberous sclerosis com-
plex.58 In addition, new treatment approaches for specific epi-
lepsies are under investigation with novel or disease-specific
targets, including AMPA receptors containing the TARPg8
subunit, expressed predominantly in the temporal lobe and of
potential relevance to mesial temporal lobe epilepsy59; KCNQ
(Kv7) potassium channels implicated in KCNQ2 developmen-
tal and epileptic encephalopathy60; and serotonin systems, rep-
resenting a target of fenfluramine, which have been reported to
cause seizure reduction in patients with Dravet syndrome.61
New routes of drug administration are also being explored.62
It will be important to carefully evaluate the utility of these new
medications in refractory epilepsy beyond the initial indica-
tions for which they are tested or approved.
In addition to new medications, more effort is needed to
understand the mechanisms of pharmacoresistance in order to
overcome refractoriness to ASMs. To this end, new animal
models together with humanized models in vitro based on
genetic data may provide an opportunity to explore mechan-
isms of resistance for those specific models with clear seizure
phenotypes for which the patient is known to be refractory to
treatment with conventional anticonvulsants. Work in this area
would benefit from integration of information about new tar-
gets into existing efforts to develop new medications that are
effective against refractory seizures. In addition to traditional
targets such as ion channels, neurotransmitter receptors, and
neurotransmitter transporters, important targets include mTOR
and related pathways, the extracellular matrix, oxidative stress,
anti-inflammatory pathways, neurosteroid systems, micro-
RNAs, and epigenetic targets include histone deacety-
lase.30,31,63-67 Cell replacement strategies to introduce
engineered cells that can support or release neuroactive sub-
stances and oligonucleotide approaches to regulate specific
genes for therapeutic gain are also opportunities to identify new
ways to treat refractory epilepsy. Moreover, clarification of the
mechanisms underlying the ketogenic diet might identify meta-
bolic and lipid targets that are relevant, the role of the gut
microbiota,68 and allow a “ketogenic diet in a pill” treatment
strategy for refractory epilepsy.
Real-Time Management of Seizures
Efforts have been made for decades to predict when seizures
will occur and provide an immediate intervention to either
prevent or terminate the seizure.69 These efforts rely on a range
of recording devices, computational algorithms to identify at-
risk periods, and active response in the form of electrical/opti-
cal stimulation or administration of a drug. Although there has
been steady progress with these strategies over the decades,
many approaches are maturing to the point where they seem
poised to provide a workable and effective therapy for a larger
number of patients.70 Indeed, the introduction in 2013 of an
FDA-approved closed loop device that detects seizures and
aborts them by deep brain stimulation has spawned many
efforts to refine stimulation parameters for better seizure con-
trol.71 New seizure prediction algorithms8 as well as new
devices may allow intravenous injection or even direct infusion
of antiseizure agents into the brain at the onset of or immedi-
ately before a seizure is predicted.72 This approach has the
capacity to harness the utility of proven pharmacological treat-
ments without the side effects of chronic exposure to drug in
blood and brain. Taken a step further, introduction of active
drug locally into the epileptic focus could provide more selec-
tive treatment of certain epileptic conditions, including refrac-
tory epilepsies, localization-related epilepsies, and status
epilepticus. Increasing power of computational algorithms7
should allow enhanced ability to predict seizures from multiple
streams of data, including electrical recordings and peripheral
readouts. In addition, miniaturization of devices can improve
the ability to deliver electrical, light, or pharmacological sti-
muli to specific regions both inside and outside of the central
nervous system. The emergence of new animal models of
genetic epilepsies provides another opportunity to test detec-
tion and seizure interruption strategies in homogeneous models
that share some basis with human epilepsy and thus might
provide robust data that can be translated to patients harboring
these variants. A range of models might stimulate improve-
ments in the low signal to noise ratio in seizure prediction and
in the abortion of seizures, such as evaluation of new biomar-
kers that change prior to seizure initiation73 and consideration
of circadian rhythms.74 Ultimately, these systems need to be
suitable for self-management in the home and other nonmedi-
cal settings in order to improve adherence and efficacy.
Taken to its logical albeit futuristic conclusion, one might
envision a paradigm shift from ASMs in the form of multiple
doses of a drug per day and steady-state blood levels (with atten-
dant side effects) to delivery systems that provide anticonvulsants
to the brain at the site they are needed and only when they are
needed, improving the quality of life of the patient. Further, each
patient’s treatment would be customized based on genetic and
molecular profiles. This form of precision medicine would elim-
inate the need for chronic and systemic nonspecific and side
effect-laden pharmacotherapy, improving efficacy and possibly
reducing the development of pharmacoresistance.
Future Directions: Challenges and
Opportunities
The genetic, technical, and conceptual advances discussed
above provide new opportunities for basic research as well as
clinical interventions. These advances offer a chance to view the
epilepsies from a different perspective and address long-term
problems that have until now have been difficult to progress.
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